Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)

NCT04972110 is registered in ClinicalTrials.gov with Repare Therapeutics as lead sponsor.

NCT NCT04972110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04972110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)
Lead sponsor
Repare Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
July 21, 2021
Completion date
November 13, 2024
Enrollment
156 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, adult